BioNTech Competitors

Gilead Sciences (NASDAQ:GILD) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Profitability

This table compares Gilead Sciences and BioNTech's net margins, return on equity and return on assets.

Volatility & Risk

Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500.

Earnings and Valuation

This table compares Gilead Sciences and BioNTech's top-line revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Gilead Sciences and BioNTech, as reported by MarketBeat.

Gilead Sciences currently has a consensus price target of $97.92, suggesting a potential upside of 49.95%. BioNTech has a consensus price target of $105.50, suggesting a potential downside of 20.44%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than BioNTech.

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 10.8% of BioNTech shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Gilead Sciences beats BioNTech on 13 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares BioNTech and Moderna's net margins, return on equity and return on assets.

Risk & Volatility

BioNTech has a beta of -1.74, meaning that its share price is 274% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.

Valuation & Earnings

This table compares BioNTech and Moderna's gross revenue, earnings per share and valuation.

BioNTech has higher revenue and earnings than Moderna. BioNTech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for BioNTech and Moderna, as provided by MarketBeat.

BioNTech presently has a consensus target price of $105.50, suggesting a potential downside of 20.44%. Moderna has a consensus target price of $149.6471, suggesting a potential downside of 6.49%. Given Moderna's higher probable upside, analysts clearly believe Moderna is more favorable than BioNTech.

Institutional & Insider Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 51.2% of Moderna shares are held by institutional investors. 29.2% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Moderna beats BioNTech on 9 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Risk & Volatility

BioNTech has a beta of -1.74, meaning that its share price is 274% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares BioNTech and Biogen's gross revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for BioNTech and Biogen, as provided by MarketBeat.

BioNTech presently has a consensus target price of $105.50, suggesting a potential downside of 20.44%. Biogen has a consensus target price of $303.5862, suggesting a potential upside of 14.22%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than BioNTech.

Institutional & Insider Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BioNTech and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats BioNTech on 12 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.

Insider & Institutional Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 87.2% of Seagen shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares BioNTech and Seagen's gross revenue, earnings per share and valuation.

Seagen has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Seagen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for BioNTech and Seagen, as provided by MarketBeat.

BioNTech presently has a consensus target price of $105.50, indicating a potential downside of 20.44%. Seagen has a consensus target price of $185.3571, indicating a potential upside of 28.54%. Given Seagen's stronger consensus rating and higher possible upside, analysts plainly believe Seagen is more favorable than BioNTech.

Profitability

This table compares BioNTech and Seagen's net margins, return on equity and return on assets.

Risk and Volatility

BioNTech has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Summary

Seagen beats BioNTech on 13 of the 15 factors compared between the two stocks.

Bio-Techne (NASDAQ:TECH) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Bio-Techne and BioNTech, as provided by MarketBeat.com.

Bio-Techne presently has a consensus target price of $367.50, indicating a potential downside of 11.31%. BioNTech has a consensus target price of $105.50, indicating a potential downside of 20.44%. Given Bio-Techne's stronger consensus rating and higher possible upside, research analysts plainly believe Bio-Techne is more favorable than BioNTech.

Volatility and Risk

Bio-Techne has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, suggesting that its stock price is 274% less volatile than the S&P 500.

Earnings & Valuation

This table compares Bio-Techne and BioNTech's top-line revenue, earnings per share and valuation.

Bio-Techne has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 10.8% of BioNTech shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Bio-Techne and BioNTech's net margins, return on equity and return on assets.

Summary

Bio-Techne beats BioNTech on 13 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Novavax (NASDAQ:NVAX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for BioNTech and Novavax, as provided by MarketBeat.com.

BioNTech presently has a consensus price target of $105.50, indicating a potential downside of 20.44%. Novavax has a consensus price target of $229.6429, indicating a potential upside of 14.06%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than BioNTech.

Volatility & Risk

BioNTech has a beta of -1.74, indicating that its share price is 274% less volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.

Valuation & Earnings

This table compares BioNTech and Novavax's revenue, earnings per share (EPS) and valuation.

Novavax has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.8% of BioNTech shares are held by institutional investors. Comparatively, 49.9% of Novavax shares are held by institutional investors. 3.3% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares BioNTech and Novavax's net margins, return on equity and return on assets.

Summary

Novavax beats BioNTech on 10 of the 14 factors compared between the two stocks.